This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

BioMarin Announces Fourth Quarter And Full Year 2013 Financial Results

Total Revenue Grows 9.5% in 2013 U.S. Commercial Launch of VIMIZIM™ Underway; Positive CHMP Opinion Received February 20

Financial Highlights ($ in millions, except per share data, unaudited)

  Three Months Ended December 31, Twelve Months Ended December 31,
  2013 2012 % Change 2013 2012 % Change
             
Total BioMarin Revenue  $ 146.9  $ 131.9 11.4%  $ 548.5  $ 500.7 9.5%
Total BioMarin Revenue             
(excluding Aldurazyme Net Product Transfer Revenue) - non-GAAP  148.5  131.2 13.2%  553.4  498.9 10.9%
Naglazyme Net Product Revenue  68.7  63.0 9.0%  271.2  257.0 5.5%
Aldurazyme BioMarin Net Product Revenue   25.9  24.6 5.3%  83.6  82.2 1.7%
Aldurazyme Royalty Revenue            
(excluding Net Product Transfer Revenue) - non-GAAP  27.5  23.9 15.1%  88.5  80.4 10.1%
Kuvan Net Product Revenue  45.3  40.0 13.3%  167.4  143.1 17.0%
Firdapse Net Product Revenue  4.3  3.4 26.5%  16.1  14.2 13.4%
VIMIZIM  0.1  --     0.1  --   
             
Non-GAAP Net Loss  $ (15.8)  $ (15.5)    $ (40.4)  $ (11.6)  
Non-GAAP Net Loss per Share (basic)  $ (0.11)  $ (0.12)    $ (0.29)  $ (0.10)  
Non-GAAP Net Loss per Share (diluted)  $ (0.11)  $ (0.12)    $ (0.30)  $ (0.12)  
             
GAAP Net Loss   $ (62.0)  $ (53.0)    $ (176.4)  $ (114.3)  
GAAP Net Loss per Share (basic)  $ (0.43)  $ (0.43)    $ (1.28)  $ (0.95)  
GAAP Net Loss per Share (diluted)  $ (0.44)  $ (0.43)    $ (1.28)  $ (0.95)  
             
Cash, cash equivalents and investments *        $1,052.4  $ 563.8 86.7%
* The cash balance at the end of 2013 includes net proceeds of $696.4 million from the Convertible Debt offering in October 2013.

SAN RAFAEL, Calif., Feb. 26, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced financial results for the fourth quarter and full year 2013.  Non-GAAP net loss was $15.8 million ($0.11 per share, basic and diluted) for the fourth quarter of 2013, compared to non-GAAP net loss of $15.5 million ($0.12 per share, basic and diluted) for the fourth quarter of 2012. GAAP net loss was $62.0 million ($0.43 per share, basic and $0.44 per share, diluted) for the fourth quarter of 2013, compared to GAAP net loss of $53.0 million ($0.43 per share, basic and diluted) for the fourth quarter of 2012. The increased non-GAAP net loss and GAAP net loss for the fourth quarter of 2013 compared to the fourth quarter of 2012 was primarily due to increased research and development expenses, including costs associated with PEG PAL, BMN 673 and BMN 270, the Company's AAV-factor VIII gene therapy drug candidate for the treatment of hemophilia A, as well as increased selling, general and administrative expenses, including costs associated with VIMIZIM launch activities, partially offset by increased net product revenues.

1 of 6

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,697.32 -183.04 -1.08%
S&P 500 1,943.91 -26.16 -1.33%
NASDAQ 4,390.8170 -72.0850 -1.62%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs